Skip to main content

Posts tagged with "Patents and IP"

  • Patents and IP

    How Do You Find A New Compound to Patent?

    I recently had a question from an interested reader, who’s outside of medicinal chemistry, wondering about how we find room to work in patent space. From his viewpoint, there seemed to be many areas that were so worked over that he found it had to see how any new project could make headway, or be… Read More
  • Patents and IP

    The Problem With Patents

    Fair warning: this is a post about patents and IP. I say that because in the past, I’ve practically been able to see the readers fleeing in real time when such things come up. Two or three of them in a row, and there would probably be nobody left around at all. But it’s a… Read More
  • Business and Markets

    Alnylam Sues Dicerna

    Here’s the latest RNAi dustup: Alnylam has filed a “trade secret misappropriation” lawsuit against Dicerna (thanks to a commenter here for mentioning this news). The real issue seems to be use of GalNAc conjugates for delivering siRNAs to the liver. Alnylam’s president, Barry Greene says that “Alnylam has led the disco… Read More
  • Business and Markets

    Nice Patent You Have There. . .

    This does not seem to me like a great advance in intellectual property law: this Bloomberg article says that some large investors are using the patent challenge process for their own purposes: Taking advantage of new rules created by Congress three years ago, hedge funds have increasingly been filing challenges to pharmaceutical patents. Some may… Read More
  • Business and Markets

    Merck, Cubist, and Hospira: The Inside

    Or as much of the inside as we’re likely to have. Thanks to @AndyBiotech on Twitter, here’s an SEC document detailing the negotiations between Merck and Cubist. It makes for interesting reading in general – you can see how a deal like this comes together, and all the places where it might have fallen apart… Read More
  • Biological News

    Who Owns CRISPR?

    Update: see also this post at Xconomy for a look at this issue. CRISPR/Cas9 is an excellent technique for gene manipulation. Its discovery is absolutely going to be the subject of a Nobel prize; I think it’s pretty much of a lock. But at the moment, there’s a vicious legal fight going on over who… Read More
  • Business and Markets

    A Slight Cubist Complication

    This probably isn’t quite as embarrassing as it looks: the very day of Merck’s bid for Cubist Pharmaceuticals, the company loses a patent case for protection of its flagship drug. Cubicin (daptomycin) is by far the main source of revenue at the company right now ($800 million last year, and continuing to climb), and as… Read More
  • Cardiovascular Disease

    Amgen Claims It All

    There’s plenty of excitement about PCSK9, the latest LDL-lowering pathway to make it deep into the clinic. You can tell that companies (and investors) have high hopes for it, since it’s heading right into a market that’s dominated by generic statins. The optimism may well be justified – for example, Sanofi and Regeneron rece… Read More
  • Patents and IP

    Compensating Inventors: Good Idea Or Not?

    As an inventor of a new drug here in the US, you are most certainly on the patents that have been filed around it. What do these patents earn for you? Well, in the US, they earn you a hearty handshake (like the one that W. C. Fields used to get when he stopped a… Read More
  • Cancer

    An Open-Source Cancer Pitch, Deconstructed

    I’m confused. Read this and see if you end up the same way. TechCrunch has the story of Isaac Yonemoto, who’s crowdsourcing a project around a potential oncology compound. It’s a derivative of sibiromycin, a compound I hadn’t come across, but it seems that it was first studied in Russia, and then at Maryland. Yonemoto’ Read More